Palatin Technologies, Inc. Common Stock (PTN) - Total Assets
Based on the latest financial reports, Palatin Technologies, Inc. Common Stock (PTN) holds total assets worth $13.23 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Palatin Technologies, Inc. Common Stock - Total Assets Trend (1996–2025)
This chart illustrates how Palatin Technologies, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see PTN market cap overview for the company's overall valuation and market capitalisation.
Palatin Technologies, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (June 2025)
Palatin Technologies, Inc. Common Stock's total assets of $13.23 Million consist of 89.4% current assets and 10.6% non-current assets. Review PTN total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $2.56 Million | 78.5% |
| Accounts Receivable | $29.47K | 0.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $290.61K | 8.9% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2025)
This chart illustrates how Palatin Technologies, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Palatin Technologies, Inc. Common Stock (PTN) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Palatin Technologies, Inc. Common Stock's current assets represent 89.4% of total assets in 2025, a decrease from 97.5% in 1996.
- Cash Position: Cash and equivalents constituted 78.5% of total assets in 2025, down from 96.5% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is cash and equivalents at 78.5% of total assets.
Palatin Technologies, Inc. Common Stock Competitors by Total Assets
Key competitors of Palatin Technologies, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Palatin Technologies, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.04 | 0.32 | 6.27 |
| Quick Ratio | 5.04 | 0.32 | 6.16 |
| Cash Ratio | 0.00 | 0.25 | 5.72 |
| Working Capital | $10.25 Million | $-6.82 Million | $55.40 Million |
Palatin Technologies, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Palatin Technologies, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.07 |
| Latest Market Cap to Assets Ratio | 5.91 |
| Asset Growth Rate (YoY) | -69.6% |
| Total Assets | $3.27 Million |
| Market Capitalization | $19.32 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Palatin Technologies, Inc. Common Stock's assets at a significant premium (5.91x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Palatin Technologies, Inc. Common Stock's assets decreased by 69.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Palatin Technologies, Inc. Common Stock (1996–2025)
The table below shows the annual total assets of Palatin Technologies, Inc. Common Stock from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $3.27 Million | -69.59% |
| 2024-06-30 | $10.74 Million | -40.12% |
| 2023-06-30 | $17.94 Million | -50.27% |
| 2022-06-30 | $36.07 Million | -46.40% |
| 2021-06-30 | $67.30 Million | -20.88% |
| 2020-06-30 | $85.05 Million | -18.79% |
| 2019-06-30 | $104.74 Million | +168.44% |
| 2018-06-30 | $39.02 Million | -31.35% |
| 2017-06-30 | $56.83 Million | +414.25% |
| 2016-06-30 | $11.05 Million | -62.50% |
| 2015-06-30 | $29.47 Million | +134.69% |
| 2014-06-30 | $12.56 Million | -49.91% |
| 2013-06-30 | $25.07 Million | +366.02% |
| 2012-06-30 | $5.38 Million | -74.59% |
| 2011-06-30 | $21.17 Million | +70.90% |
| 2010-06-30 | $12.39 Million | -6.14% |
| 2009-06-30 | $13.20 Million | -30.98% |
| 2008-06-30 | $19.12 Million | -55.30% |
| 2007-06-30 | $42.78 Million | +6.83% |
| 2006-06-30 | $40.05 Million | +13.88% |
| 2005-06-30 | $35.17 Million | +44.25% |
| 2004-06-30 | $24.38 Million | +7.30% |
| 2003-06-30 | $22.72 Million | +83.85% |
| 2002-06-30 | $12.36 Million | -13.24% |
| 2001-06-30 | $14.24 Million | +60.31% |
| 2000-06-30 | $8.89 Million | +89.05% |
| 1999-06-30 | $4.70 Million | -27.69% |
| 1998-06-30 | $6.50 Million | -53.90% |
| 1997-06-30 | $14.10 Million | +100.25% |
| 1996-06-30 | $7.04 Million | -- |
About Palatin Technologies, Inc. Common Stock
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, … Read more